Mentice's CEO Göran Malmberg to present the company's Year-end Report Q4 2021 at a webcast conference call on February 3rd at 9:30 CET
STOCKHOLM, Jan. 27, 2022 /PRNewswire/ -- Mentice AB (STO: MNTC) announces that the company will present its year-end report via a webcast conference call with the opportunity for interested parties to ask questions to CEO Göran Malmberg and CFO Gunilla Andersson.
To register for the presentation of the Year-end Report Q4 for the period October ? December 2021, which will be held on February 3rd at 09.30 CET, visit www.mentice.com/financial-reports-presentations.
The presentation will be held in English. Participants are advised to register at least a few minutes in advance.
For further information, please contact: Göran Malmberg, CEO, Mentice Email: [email protected] Tel US: +1 (312) 860 5610 Tel Sweden: +46 (0) 703 09 22 22
Market place: Nasdaq First North Premier, Stockholm | Ticker symbol: MNTC Certified Adviser: FNCA Sweden AB, tel +46 8 528 00 399 e-post [email protected]
Hangzhou Tigermed Consulting Co., Ltd. ("Tigermed" or the "company") (Stock code: 300347.SZ / 3347.HK), a leading global provider of integrated research and development solutions for biopharmaceutical and medical device industry, announced its annual...
Caris Life Sciences®(Caris), the leading next-generation AI TechBio company and precision medicine pioneer that is actively developing and delivering innovative solutions to revolutionize healthcare and improve the human condition using molecular...
The collagen water market is booming thanks to the growing popularity of health and beauty products. Consumers are more interested in skincare and healthy eating, which is driving manufacturers to create collagen-infused drinks and cosmetics. A new...
Viavi Solutions Inc. (VIAVI) today announced it has participated in the 2024 RIC Forum, March 26-28, in Dallas, Texas. The company contributed its TeraVM RIC Test and TM500 Network Tester to multiple demonstrations, building on collaborations at MWC...
Three clinical programs present diversified opportunities in and outside the existing anti-VEGF market and are being progressed toward Phase 3 value inflection points New Phase 3 GLOW2 study of tarcocimab in diabetic retinopathy actively...
The "PCR Markets. Forecasts for qPCR, dPCR, Singleplex & Multiplex Markets and by Application, Product and Place. With Executive and Consultant Guides, Including Customized Forecasting and Analysis. 2023 to 2027" report has been added to...